1[1]Dumont FJ. FK506, an immunosuppressant targeting calcineurin function[J]. Curr Med Chem, 2000, 7(7): 731.
2[2]Cho CS, Chang Z, Elkahwaji J, et al. Rapamycin antagonizes cyclosporine A - and tacrolimus(FK506) - mediated augmentation of linker for activation of T cell expression in T cell[J]. Int Immunol, 2003, 15 ( 11 ): 1369.
3[3]Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cell by immunosuppressive drugs[J]. Clin Exp Immunol, 2002, 128(2): 255.
4[4]Platz KP, Mueller AR, Spree E, et al. Liver transplantation foralcoholic cirrhosis[J]. Transpl Int, 2000,13 (Suppl 1): S127.
5[6]Martins L, Henriques AC, Dias L, et al. Conversion to tacrolimus in case problem kidney transplant recipients under cyclosporinebased immunosuppression[J]. Transplant Proc, 2000, 32(8): 2636.
6[7]Thorp M, Demattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol[J]. Transplantation, 2000, 69(6): 1218.
7[8]Amitage JM, Kormos RL, Fung J. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation[J]. Transplant Proc, 1991, 23 (28): 3054.
8[9]Von Steinbuchel N, Limm H, Leopold C, et al. Assessment of health - related quality - life in patients after heart transplantation under therapy with tacrolimus of cyclosporine [ J ]. Transpl Int,2000, 13(Suppl 1): S609.
9[10]David Grant on Behalf of the International Intestinal Transplant Registry. Current results of intestinal transplantation [J ]. Lancet,1996, 347: 1801.
10[11]Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft- versus -host disease with sysaenic administration of FK506 and cotisosteroids [J].Cornea, 2001, 20(4): 430.
